Mubadala’s KELIX bio buys four GlobalOne Healthcare pharma assets

Image credit: Emirates News Agency

Mubadala-backed KELIX bio has acquired a 100 per cent stake in four of GlobalOne Healthcare Holding’s pharma assets, which include Bioventure, Bioventure Healthcare, Gulf Inject and Wellpharma.

The acquisition marks a significant step forward for Abu Dhabi state investor in the life sciences sector, positioning the UAE as a key player in the global market and fostering economic growth. It aligns with government initiatives such as ‘Operation 300bn’ and ‘Make it in the Emirates’, which aim to strengthen the country’s manufacturing sector.

GlobalOne’s pharma assets include cutting-edge biopharma and IV solutions manufacturing. Integrating these assets into KELIX Bio’s ecosystem significantly advances its expanded capabilities.

“This acquisition reinforces our strategic intent to position the UAE at the forefront of the life sciences ecosystem on a global scale. It contributes to our nation’s economic diversification, creates valuable socio-economic returns, and reaffirms Mubadala’s ambitions within the sector,” said Ismail Ali Abdulla, head of UAE Clusters at Mubadala’s UAE Investments Platform.

“Being a responsible investor, we continue to nurture future-centric solutions that boost our nation’s GDP, increase job creation, foster innovation, and strengthen medical security, shaping the future of our communities with lasting impact.”

The deal advances Mubadala’s efforts to establish a national pharma champion based in Abu Dhabi. It enhances the UAE’s pharmaceutical infrastructure, addresses prevalent diseases, secures drug supply, reduces healthcare costs and progresses the nation toward a knowledge-based economy.

Mubadala acquired KELIX bio in September. Prior to Mubadala’s acquisition, KELIX bio was held by a consortium of investors, including Development Partners International, British International Investment, and the European Bank for Reconstruction and Development.

Read: Abu Dhabi fund Mubadala’s asset under management rise to $302bn